Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment

Pharmacotherapy

Volumn 37, Issue 4, 2017, Pages 412-419

  Stanton, Brooke E ^a   Barasch, Naomi S ^a   Tellor, Katie B ^b  

^a MISSOURI BAPTIST MEDICAL CENTER   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

anticoagulation; cardiology; dialysis; end stage renal disease; renal failure

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; CREATININE; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; SEVERE RENAL IMPAIRMENT; VENOUS THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED; COHORT ANALYSIS; COMMUNITY HOSPITAL; COMPARATIVE STUDY; COMPLICATION; HEMODIALYSIS; HEMORRHAGE; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEMORRHAGE; HOSPITALS, COMMUNITY; HUMANS; MALE; PERITONEAL DIALYSIS; PYRAZOLES; PYRIDONES; RENAL DIALYSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 85017315824     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1905     Document Type: Article

References (18)

1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–76.
2. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.
3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
4. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799–808.
5. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–100.
6. Bristol-Myers Squibb Company. Eliquis (apixaban) package insert. Princeton, NJ; 2012. Revised 2016 July.
7. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331–9.
8. Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010;159:348–53.
9. Chang M, Yu Z, Shenker A, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016;56:637–45.
10. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016;56:628–36.
11. Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016;43:229–36.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
13. Tellor KB, Patel S, Armbruster AL, Daly MW. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther 2015;40:447–51.
14. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1–138.
15. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263–72.
16. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95(3):315–28.
17. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87(2):144–52.
18. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689–96.